Trial Profile

An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aciclovir (Primary) ; Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms SELECT
Sponsors Amgen

Most Recent Events

19 Nov 2024 Status changed from active, no longer recruiting to completed.
01 Jun 2024 Results assessing efficacy and safety of weekly carfilzomib, pomalidomide, and dexamethasone in early RRMM patients published in the Leukemia and Lymphoma
10 Feb 2024 The trial has been discontinued in Greece according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com